Financial Results - LENZ Therapeutics, Inc. reported preliminary, unaudited financial results for Q4 2025, ending December 31, 2025[4] - The financial results are subject to change upon completion of the company's accounting and annual audit procedures[4] - A press release detailing these results was issued on January 7, 2026[4] - The financial statements and additional disclosures are necessary for a complete understanding of the company's financial position[4] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025 Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025 SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the ...

LENZ Therapeutics (LENZ) announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZ for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under the terms ...

Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercializ ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving LENZ Therapeutics, Inc. following a significant drop in its stock price due to adverse event reports related to its product [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of LENZ Therapeutics, Inc. and is looking into whether the company and its officers or directors have engaged in fraudulent activities [1]. - The investigation was prompted by a report of a retinal tear associated with LENZ's VIZZ eye drop, which was recorded in the FDA's adverse event reporting systems [3]. Group 2: Stock Price Impact - Following the adverse event report on December 12, 2025, LENZ's stock price decreased by $6.36 per share, representing a decline of 25.96%, closing at $18.14 per share on that date [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Company Overview - LENZ Therapeutics, Inc. experienced a significant decline in share price, falling approximately 25% following reports of an "adverse event" related to its leading drug, VIZZ [1] - The decline in shares has continued, with the stock now down around 30% from its previous levels [1] Market Reaction - The market's reaction to the adverse event indicates heightened investor concern regarding the safety and efficacy of VIZZ, which could impact future sales and the company's overall valuation [1]

Core Insights - Lexston Mining Corporation has appointed Buddy Doyle to its newly established Advisory Board, bringing 40 years of experience in mineral exploration [1][4] - Mr. Doyle has a notable history with Rio Tinto PLC, where he served as Exploration Vice President and was involved in significant discoveries such as the Minifie gold deposits and Diavik diamond deposits [2][3] - The company has granted incentive stock options to directors, officers, and consultants to purchase up to 400,000 common shares at a price of $0.115 per share, exercisable for five years [4] Company Overview - Lexston Mining Corporation is a Canadian mineral exploration company focused on acquiring and developing mineral projects to enhance stakeholder value, with current projects located in British Columbia and Nevada [5] - The company trades on the OTCQB Venture Market, which serves early-stage and developing companies, ensuring compliance with reporting and management certification processes [6]

Core Insights - Nevis Brands Inc. has announced significant corporate updates, including product launches and financial agreements, positioning itself for growth in the cannabis beverage market [1][2][3]. Product Launches - The company has relaunched its Major(™) beverages in Arizona, including Major 100mg Fruit Punch, Blackberry Lemonade, and Blueberry, which are now available in multiple dispensaries across the state [1]. - Nevis Brands has secured a purchase agreement for its Happy Apple(™) hemp-derived THC beverages in Ohio, enhancing the brand's presence in a growing market [2]. Financial Developments - Nevis has reached an agreement with SoRSE Technology to make an additional payment of $75,000 towards the remaining $100,000 principal of a note, with plans to pay the remaining $25,000 plus estimated $55,000 in interest by June 2026 [3][4]. - The company aims to complete the payment of the note and allocate additional cash towards expanding its product portfolio in 2026 [4]. Company Overview - Nevis Brands Inc. is focused on building a portfolio of iconic recreational cannabis brands and operates in regulated dispensary markets through strategic partnerships and licensed production facilities [5]. - The company also sells hemp-derived THC products through its website and select distributors [5].

Question-and-Answer SessionObviously, a tremendous amount of progress since you did the reverse merge, did the Phase III data successfully built the commercial infrastructure, got the approval and now, of course, have launched the product biz. So tell us where you are? Tell us a little bit about the early launch? How it's going? What you're preparing for 1Q just -- set the stage?Evert SchimmelpenninkPresident, CEO, Secretary & Director Absolutely. Thanks, Yigal. Obviously, thanks for the invite. Great to be ...

Financial Data and Key Metrics Changes - The company launched its product in early October after receiving approval in late July, and within the first four weeks, it recorded 5,000 scripts written by 2,500 doctors, indicating strong initial interest and confidence in the product [27][29]. - Awareness of the product among doctors exceeded 90%, which is considered exceptional for a new product [12]. Business Line Data and Key Metrics Changes - The company has fully operational e-pharmacy and retail pharmacy channels, allowing consumers to order the product online or pick it up at local pharmacies [10][9]. - The company is focusing on getting samples into the hands of doctors to build confidence and awareness, with 70,000 samples distributed across approximately 7,000 offices [51]. Market Data and Key Metrics Changes - The product is seeing a demographic skew towards females, with 60% of orders coming from women, primarily in the 45-55 age group [18][66]. - The company is targeting urban areas for its product launch, aligning with its initial market segmentation strategy [66]. Company Strategy and Development Direction - The company plans to turn on direct-to-consumer (DTC) marketing in Q1, which is expected to drive new patient starts and increase product awareness [76]. - The company is focused on establishing its product as a cornerstone of a larger portfolio, with plans for business development and mergers and acquisitions post-2026 [41]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's performance based on positive feedback from doctors and patients, noting that the product works effectively for nearly all patients [3][5]. - The company is aware of the competitive landscape, particularly regarding other products like Vuity, and believes its product offers superior efficacy and duration of effect [44][45]. Other Important Information - The company has partnerships in place for international markets, including South Korea and Greater China, and is pursuing registration in Europe [36][37]. - The supply chain is robust, with the product being manufactured in the U.S. and imported duty-free, ensuring cost-effectiveness [38]. Q&A Session Summary Question: How is the early launch going? - The company reported strong initial metrics with 5,000 scripts written and 2,500 doctors participating within the first four weeks, indicating significant interest [27][29]. Question: What is the strategy for DTC marketing? - The company plans to launch DTC marketing in Q1, focusing on digital platforms and utilizing a celebrity spokesperson to enhance brand awareness [76][18]. Question: How does the company view its competition? - Management highlighted that their product is the only pupil-selective miotic and believes it has a significant advantage over competitors like Vuity, which has shown limited efficacy [42][44]. Question: What are the plans for international expansion? - The company has submitted an NDA in South Korea and has partnerships in place for Greater China and Canada, with plans to explore further international opportunities [36][37]. Question: How is the product being received in the market? - Feedback from doctors and patients has been overwhelmingly positive, with reports of effective near vision improvement and minimal side effects [3][5].